MedTrace Logo

Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)

NCT01554813 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2012-09-06

No results posted yet for this study

Summary

The clinical trial was conducted in Jintan City of Jiangsu Province, China in May, 2006. The purpose of the clinical trial was to evaluate the safety and immunogenicity against Hualan's Influenza Vaccine (Split Virion), Inactivated (0.5ml) administered on age 6 months and old population.

Conditions

Interventions

BIOLOGICAL

Influenza split vaccine of 15 μg HA

60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime

BIOLOGICAL

Influenza split vaccine of 15 μg HA

558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime

BIOLOGICAL

Influenza split vaccine

280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime

Sponsors & Collaborators

  • Hualan Biological Engineering, Inc.

    lead INDUSTRY

Principal Investigators

  • Feng-cai Zhu, M.D. · Jiangsu Provicial Center for Disease Provention and Control

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-07-31
Completion
2006-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554813 on ClinicalTrials.gov